Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 CAD | +0.75% |
|
-2.47% | -15.19% |
07/06 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
28/05 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.19% | 7.78Cr | |
-2.46% | 2.39TCr | |
+14.23% | 870.36Cr | |
+1.47% | 829.3Cr | |
-32.92% | 669.77Cr | |
+18.62% | 538.27Cr | |
+1.10% | 407.87Cr | |
-9.24% | 379.19Cr | |
-10.20% | 329.84Cr | |
+7.11% | 318.76Cr |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan